Paper Details

  1. Home
  2. Paper Details

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial.

Author: BaetenDominique, BaraliakosXenofon, BekStephan, BertolinoArthur P, BrachatArndt, BraunJürgen, EmeryPaul, GsteigerSandro, HueberWolfgang, KellnerHerbert, LandewéRobert, LaurentDidier, LiYali, McInnesIain, ParamartaJacqueline, SieperJoachim, WangYing A, WeiJiawei, WollenhauptJürgen, WordsworthPaul, WrightAndrew M, van LaarJacob M, van der HeijdeDésirée

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study will assess the efficacy and safety of secukinumab, an anti-IL-17A monoclonal antibody, in treating patients with active ankylosing spondylitis.
Paper Details　
Original Abstract of the Article :
Ankylosing spondylitis is a chronic immune-mediated inflammatory disease characterised by spinal inflammation, progressive spinal rigidity, and peripheral arthritis. Interleukin 17 (IL-17) is thought to be a key inflammatory cytokine in the development of ankylosing spondylitis, the prototypical for...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(13)61134-4

データ提供：米国国立医学図書館（NLM）

Targeting Interleukin 17 in Ankylosing Spondylitis

This study focuses on the intriguing realm of inflammatory diseases, particularly ankylosing spondylitis, a chronic condition characterized by spinal inflammation and stiffness. The researchers investigated the efficacy of secukinumab, an anti-interleukin-17A monoclonal antibody, in treating patients with active ankylosing spondylitis. This study delves into the crucial role of interleukin-17 (IL-17) in the development of this disease, providing insights into potential therapeutic strategies.

Secukinumab Shows Promise in Ankylosing Spondylitis Treatment

The study reveals that secukinumab demonstrated efficacy and safety in treating patients with active ankylosing spondylitis. This finding suggests that targeting IL-17 with monoclonal antibodies may hold promising therapeutic potential for this debilitating condition. The study's meticulous design, employing a randomized, double-blind, placebo-controlled trial, adds further credence to its findings.

Navigating Ankylosing Spondylitis: A Journey Through Stiffness

Ankylosing spondylitis can make everyday activities challenging, like reaching for a glass of water or tying your shoes. However, this study offers hope for individuals living with this condition. With the potential of secukinumab to alleviate symptoms and improve quality of life, patients can embrace a more flexible future. This research is like a refreshing oasis in the desert of ankylosing spondylitis, offering a glimmer of hope for those seeking relief from this chronic condition.

Dr.Camel's Conclusion

This study showcases the promise of targeting IL-17 in the treatment of ankylosing spondylitis. It's like using a compass to navigate the vast desert of this debilitating condition. With secukinumab as a potential tool, patients can explore a path towards improved mobility and quality of life. It's a reminder that even in the face of seemingly insurmountable challenges, there's always hope for a brighter horizon.
Date :
  1. Date Completed 2013-12-05
  2. Date Revised 2022-03-21
Further Info :

Pubmed ID

24035250

DOI: Digital Object Identifier

10.1016/S0140-6736(13)61134-4

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.